Skip to main content
. 2012 Feb 15;7(2):e31070. doi: 10.1371/journal.pone.0031070

Figure 3. Significant accumulation of P/2C5 in MDA-MB-468 breast tumor in vivo.

Figure 3

(3a), An MDA-MB-468 subcutaneous tumor-bearing mouse was administered with P/2C5 intravenously. 24 hours later, the animal showed drug distribution mostly in the tumor, as well as in kidney and liver (drug clearing organs). (3b), Other than in kidney and liver, the drug was seen exclusively in the tumor.